Sanofi and GlaxoSmithKline announced the initiation of a new phase 2 study to select the most appropriate antigen dosage for phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate.
The companies made the announcement on Monday
According to the companies, the new phase 2 study will enable them to identify the final vaccine formulation for adults of all ages.
The companies noted that the trial will consist of equal numbers of adults 18 to 59 years and those 60 years and above.
In December, phase 1/2 study results showed an immune response comparable to patients who had recovered from COVID-19 in adults aged between 18 to 49 years, but a lower immune response in older adults.
The companies anticipate further progress of this vaccine candidate to phase 3 in the second quarter of 2021 if the phase 2 study is successful.
It stressed that the vaccine is projected to be available in the fourth quarter of 2021 if approved.
dpa-AFX
